These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29463233)

  • 21. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up.
    Clemens JD; Sack DA; Harris JR; Van Loon F; Chakraborty J; Ahmed F; Rao MR; Khan MR; Yunus M; Huda N
    Lancet; 1990 Feb; 335(8684):270-3. PubMed ID: 1967730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of oral cholera vaccine as a vaccine probe to determine the burden of culture-negative cholera.
    Im J; Islam MT; Ahmmed F; Kim DR; Chon Y; Zaman K; Khan AI; Ali M; Marks F; Qadri F; Clemens JD
    PLoS Negl Trop Dis; 2019 Mar; 13(3):e0007179. PubMed ID: 30870416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccine Protection of Bangladeshi infants and young children against cholera: implications for vaccine deployment and person-to-person transmission.
    Ali M; Emch M; Yunus M; Sack D; Lopez AL; Holmgren J; Clemens J
    Pediatr Infect Dis J; 2008 Jan; 27(1):33-7. PubMed ID: 18162935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age.
    Saha A; Chowdhury MI; Khanam F; Bhuiyan MS; Chowdhury F; Khan AI; Khan IA; Clemens J; Ali M; Cravioto A; Qadri F
    Vaccine; 2011 Oct; 29(46):8285-92. PubMed ID: 21907255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neighborhood-targeted and case-triggered use of a single dose of oral cholera vaccine in an urban setting: Feasibility and vaccine coverage.
    Parker LA; Rumunu J; Jamet C; Kenyi Y; Lino RL; Wamala JF; Mpairwe AM; Muller V; Llosa AE; Uzzeni F; Luquero FJ; Ciglenecki I; Azman AS
    PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005652. PubMed ID: 28594891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccines for preventing cholera: killed whole cell or other subunit vaccines (injected).
    Graves PM; Deeks JJ; Demicheli V; Jefferson T
    Cochrane Database Syst Rev; 2010 Aug; 2010(8):CD000974. PubMed ID: 20687062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial.
    Kanungo S; Paisley A; Lopez AL; Bhattacharya M; Manna B; Kim DR; Han SH; Attridge S; Carbis R; Rao R; Holmgren J; Clemens JD; Sur D
    Vaccine; 2009 Nov; 27(49):6887-93. PubMed ID: 19761838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of adding hand-washing and water disinfection promotion to oral cholera vaccination on diarrhoea-associated hospitalization in Dhaka, Bangladesh: evidence from a cluster randomized control trial.
    Najnin N; Leder K; Qadri F; Forbes A; Unicomb L; Winch PJ; Ram PK; Leontsini E; Nizame FA; Arman S; Begum F; Biswas SK; Clemens JD; Ali M; Cravioto A; Luby SP
    Int J Epidemiol; 2017 Dec; 46(6):2056-2066. PubMed ID: 29025064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The interplay between WASH practices and vaccination with oral cholera vaccines in protecting against cholera in urban Bangladesh: Reanalysis of a cluster-randomized trial.
    Chowdhury F; Aziz AB; Ahmmed F; Ahmed T; Kang SS; Im J; Park J; Tadesse BT; Islam MT; Kim DR; Hoque M; Pak G; Khanam F; McMillan NAJ; Liu X; Zaman K; Khan AI; Kim JH; Marks F; Qadri F; Clemens JD
    Vaccine; 2023 Mar; 41(14):2368-2375. PubMed ID: 36898931
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial.
    Qadri F; Ali M; Chowdhury F; Khan AI; Saha A; Khan IA; Begum YA; Bhuiyan TR; Chowdhury MI; Uddin MJ; Khan JAM; Chowdhury AI; Rahman A; Siddique SA; Asaduzzaman M; Akter A; Khan A; Ae You Y; Siddik AU; Saha NC; Kabir A; Riaz BK; Biswas SK; Begum F; Unicomb L; Luby SP; Cravioto A; Clemens JD
    Lancet; 2015 Oct; 386(10001):1362-1371. PubMed ID: 26164097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Socioeconomic risk factors for cholera in different transmission settings: An analysis of the data of a cluster randomized trial in Bangladesh.
    Saha A; Hayen A; Ali M; Rosewell A; Clemens JD; Raina MacIntyre C; Qadri F
    Vaccine; 2017 Sep; 35(37):5043-5049. PubMed ID: 28765003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delayed second dose of oral cholera vaccine administered before high-risk period for cholera transmission: Cholera control strategy in Lusaka, 2016.
    Ferreras E; Matapo B; Chizema-Kawesha E; Chewe O; Mzyece H; Blake A; Moonde L; Zulu G; Poncin M; Sinyange N; Kasese-Chanda N; Phiri C; Malama K; Mukonka V; Cohuet S; Uzzeni F; Ciglenecki I; Danovaro-Holliday MC; Luquero FJ; Pezzoli L
    PLoS One; 2019; 14(8):e0219040. PubMed ID: 31469853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mass vaccination with a two-dose oral cholera vaccine in a long-standing refugee camp, Thailand.
    Phares CR; Date K; Travers P; Déglise C; Wongjindanon N; Ortega L; Bhuket PR
    Vaccine; 2016 Jan; 34(1):128-33. PubMed ID: 26549363
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam.
    Thiem VD; Deen JL; von Seidlein L; Canh DG; Anh DD; Park JK; Ali M; Danovaro-Holliday MC; Son ND; Hoa NT; Holmgren J; Clemens JD
    Vaccine; 2006 May; 24(20):4297-303. PubMed ID: 16580760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Study on the immunogenicity and safety of recombinant B-subunit/whole cell cholera vaccine infused with antacids in healthy population at ages of 2-6 years].
    Huang T; Li RC; Liu DP
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Sep; 51(9):827-831. PubMed ID: 28881549
    [No Abstract]   [Full Text] [Related]  

  • 36. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
    García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R
    Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Field trial of oral cholera vaccines in Bangladesh: results of one year of follow-up.
    Clemens JD; Harris JR; Sack DA; Chakraborty J; Ahmed F; Stanton BF; Khan MU; Kay BA; Huda N; Khan MR
    J Infect Dis; 1988 Jul; 158(1):60-9. PubMed ID: 3392421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccines for preventing cholera.
    Graves P; Deeks J; Demicheli V; Pratt M; Jefferson T
    Cochrane Database Syst Rev; 2000; (4):CD000974. PubMed ID: 11034693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor.
    Chen WH; Cohen MB; Kirkpatrick BD; Brady RC; Galloway D; Gurwith M; Hall RH; Kessler RA; Lock M; Haney D; Lyon CE; Pasetti MF; Simon JK; Szabo F; Tennant S; Levine MM
    Clin Infect Dis; 2016 Jun; 62(11):1329-1335. PubMed ID: 27001804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam.
    Trach DD; Cam PD; Ke NT; Rao MR; Dinh D; Hang PV; Hung NV; Canh DG; Thiem VD; Naficy A; Ivanoff B; Svennerholm AM; Holmgren J; Clemens JD
    Bull World Health Organ; 2002; 80(1):2-8. PubMed ID: 11884967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.